Posted by Michael Wonder on 16 Jan 2024
Ono Pharm’s Braftovi for BRAF V600E mutated colorectal cancer gets reimbursement
11 January 2024 - Ono Pharmaceutical Korea said Thursday that Braftovi (encorafenib), a targeted therapy for BRAF V600E mutated metastatic colorectal cancer, has been approved for health insurance coverage effective 1 January 2024.
The reimbursement will be available in combination with cetuximab for patients with metastatic colorectal cancer who have received prior therapy and have a confirmed BRAF V600E mutation.
